ADC Therapeutics (ADCT) Leases (2019 - 2023)
Historic Leases for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $10.3 million.
- ADC Therapeutics' Leases rose 5313.06% to $10.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $10.3 million, marking a year-over-year increase of 5313.06%. This contributed to the annual value of $6.9 million for FY2022, which is 9628470.13% up from last year.
- Per ADC Therapeutics' latest filing, its Leases stood at $10.3 million for Q3 2023, which was up 5313.06% from $11.0 million recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Leases registered a high of $11.2 million during Q1 2023, and its lowest value of $3402.0 during Q3 2020.
- In the last 5 years, ADC Therapeutics' Leases had a median value of $6.8 million in 2022 and averaged $5.9 million.
- Its Leases has fluctuated over the past 5 years, first surged by 22153433.27% in 2021, then crashed by 2455.12% in 2022.
- Over the past 5 years, ADC Therapeutics' Leases (Quarter) stood at $4898.0 in 2019, then plummeted by 30.54% to $3402.0 in 2020, then soared by 110.58% to $7164.0 in 2021, then soared by 96284.7% to $6.9 million in 2022, then soared by 48.76% to $10.3 million in 2023.
- Its Leases was $10.3 million in Q3 2023, compared to $11.0 million in Q2 2023 and $11.2 million in Q1 2023.